# PRDM6

## Overview
PRDM6 is a gene that encodes the PR/SET domain 6 protein, which is a member of the PRDM family of proteins. This protein is characterized by the presence of a PR domain and multiple zinc finger motifs, which are integral to its function in transcriptional regulation. Although PR/SET domain 6 lacks intrinsic histone methyltransferase activity, it plays a crucial role in transcriptional repression by interacting with chromatin-remodeling proteins, such as histone deacetylases and histone methyltransferases, to modulate gene expression. The protein is particularly significant in the regulation of vascular smooth muscle cells (VSMCs) and endothelial cell precursors, influencing cell proliferation, differentiation, and apoptosis. PRDM6's involvement in vascular development and its association with congenital heart defects, such as patent ductus arteriosus, underscore its clinical significance (Davis2006PRISMPRDM6; Wu2008PRDM6; Li2016Mutations).

## Structure
PRDM6 is a protein characterized by the presence of a PR domain and multiple zinc finger motifs, which are typical features of the PRDM family of proteins. The PR domain is related to the SET domain, known for its role in histone methylation, although PRDM6 itself lacks intrinsic histone methyltransferase activity due to a substitution in the NHSC motif of its PR/SET domain (Davis2006PRISMPRDM6). The protein contains four Krüppel-like zinc fingers at the carboxyl terminus, which are crucial for DNA binding and nuclear localization (Wu2008PRDM6; Li2016Mutations).

PRDM6 undergoes alternative splicing, resulting in multiple isoforms with variations in the presence of the PR domain and zinc fingers. For example, the PRDM6/33# isoform lacks the PR domain due to the deletion of exons 3-5, and PRDM6/36# has a unique carboxyl-terminal sequence due to alternative splicing in intron 7, leading to the loss of the fourth zinc finger (Wu2008PRDM6).

The protein is involved in transcriptional repression and interacts with chromatin-remodeling proteins, including histone deacetylases and histone methyltransferases, to mediate its function (Davis2006PRISMPRDM6; Gewies2013Prdm6). These interactions suggest a complex quaternary structure involving protein-protein interactions.

## Function
PRDM6 is a nuclear protein that functions as a histone methyltransferase, playing a critical role in the transcriptional regulation of vascular smooth muscle cells (VSMCs). In healthy human cells, PRDM6 is involved in histone lysine methylation, specifically reducing dimethylation of H3K9 and increasing dimethylation of H4K20. This activity is crucial for regulating gene expression related to VSMC contractility, including the suppression of MYH11, a contractile protein in VSMCs (Li2016Mutations).

PRDM6 acts as a transcriptional repressor, promoting a proliferative gene program in smooth muscle cells by recruiting histone methyltransferases like G9a, despite lacking intrinsic HMT activity. It represses genes linked to a differentiated phenotype, such as myocardin and GATA-6, while inducing genes associated with a proliferative phenotype, like amphiregulin and Wnt4 (Davis2006PRISMPRDM6).

PRDM6 is also involved in vascular development, particularly in endothelial cell precursors, where it inhibits endothelial cell proliferation, survival, and differentiation. It is enriched in vascular precursors and may influence cell fate decisions, favoring smooth muscle over endothelial differentiation (Wu2008PRDM6).

## Clinical Significance
Mutations in the PRDM6 gene have been associated with isolated nonsyndromic patent ductus arteriosus (PDA), a congenital heart defect characterized by the failure of the ductus arteriosus to close after birth. This condition can lead to complications such as pulmonary arterial hypertension and congestive heart failure. The study by Li et al. identified specific missense mutations in PRDM6 that segregate with PDA in affected individuals. These mutations, located in the zinc-finger domain of PRDM6, impair the protein's nuclear localization and histone methyltransferase activity, leading to a loss of function. This results in altered histone modification patterns and affects the transcriptional regulation of vascular smooth muscle cell contractile proteins, contributing to the pathogenesis of PDA (Li2016Mutations).

Alterations in PRDM6 expression have also been linked to hypertension. The gene is involved in the regulation of renin-producing cells, which are crucial in the renin-angiotensin-aldosterone system that controls blood pressure. Dysregulation of PRDM6 can lead to increased renin and aldosterone levels, contributing to hypertension. Genetic variants in PRDM6 have been associated with blood pressure traits, and alterations in its expression may lead to hypertension by increasing the number of renin-producing cells (Gunawardhana2023A).

## Interactions
PRDM6 is known to interact with several proteins involved in chromatin remodeling and transcriptional regulation. It forms complexes with histone deacetylases (HDAC1, -2, and -3) and heterochromatin protein-1 (HP1-β), which are crucial for its function as a transcriptional repressor. These interactions are facilitated by the PR domain and zinc finger motifs of PRDM6, which are essential for its localization in the nucleus and its ability to form homodimers (Davis2006PRISMPRDM6).

PRDM6 also interacts with the histone methyltransferase G9a, enhancing its activity and suggesting a role in gene silencing through histone modification. Although PRDM6 lacks intrinsic histone methyltransferase activity, it recruits G9a to establish transcriptional repression (Davis2006PRISMPRDM6; Wu2008PRDM6). The protein can also associate with the transcriptional coactivator p300, indicating its potential involvement in both transcriptional repression and activation (Davis2006PRISMPRDM6).

In endothelial cells, PRDM6 has been shown to induce apoptosis and cell cycle arrest, possibly through interactions with other proteins that modulate chromatin structure and gene expression (Wu2008PRDM6). These interactions highlight PRDM6's role in regulating cellular phenotype and gene expression through complex protein networks.


## References


[1. (Davis2006PRISMPRDM6) Christopher A. Davis, Michael Haberland, Michael A. Arnold, Lillian B. Sutherland, Oliver G. McDonald, James A. Richardson, Geoffrey Childs, Stephen Harris, Gary K. Owens, and Eric N. Olson. Prism/prdm6, a transcriptional repressor that promotes the proliferative gene program in smooth muscle cells. Molecular and Cellular Biology, 26(7):2626–2636, April 2006. URL: http://dx.doi.org/10.1128/mcb.26.7.2626-2636.2006, doi:10.1128/mcb.26.7.2626-2636.2006. This article has 110 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.26.7.2626-2636.2006)

[2. (Wu2008PRDM6) Yaxu Wu, James E. Ferguson, Hong Wang, Rusty Kelley, Rongqin Ren, Holly McDonough, James Meeker, Peter C. Charles, Hengbin Wang, and Cam Patterson. Prdm6 is enriched in vascular precursors during development and inhibits endothelial cell proliferation, survival, and differentiation. Journal of Molecular and Cellular Cardiology, 44(1):47–58, January 2008. URL: http://dx.doi.org/10.1016/j.yjmcc.2007.06.008, doi:10.1016/j.yjmcc.2007.06.008. This article has 44 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.yjmcc.2007.06.008)

[3. (Gunawardhana2023A) Kushan L. Gunawardhana, Lingjuan Hong, Trojan Rugira, Severin Uebbing, Joanna Kucharczak, Sameet Mehta, Dineth R. Karunamuni, Brenda Cabera-Mendoza, Neeru Gandotra, Curt Scharfe, Renato Polimanti, James P. Noonan, and Arya Mani. A systems biology approach identifies the role of dysregulated prdm6 in the development of hypertension. Journal of Clinical Investigation, February 2023. URL: http://dx.doi.org/10.1172/jci160036, doi:10.1172/jci160036. This article has 7 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci160036)

[4. (Li2016Mutations) Na Li, Lakshman Subrahmanyan, Emily Smith, Xiaoqing Yu, Samir Zaidi, Murim Choi, Shrikant Mane, Carol Nelson-Williams, Mohaddeseh Behjati, Mohammad Kazemi, Mohammad Hashemi, Mohsen Fathzadeh, Anand Narayanan, Likun Tian, Farhad Montazeri, Mitra Mani, Michael L. Begleiter, Brian G. Coon, Henry T. Lynch, Eric N. Olson, Hongyu Zhao, Jürgen Ruland, Richard P. Lifton, and Arya Mani. Mutations in the histone modifier prdm6 are associated with isolated nonsyndromic patent ductus arteriosus. The American Journal of Human Genetics, 98(6):1082–1091, June 2016. URL: http://dx.doi.org/10.1016/j.ajhg.2016.03.022, doi:10.1016/j.ajhg.2016.03.022. This article has 21 citations.](https://doi.org/10.1016/j.ajhg.2016.03.022)

[5. (Gewies2013Prdm6) Andreas Gewies, Mercedes Castineiras-Vilarino, Uta Ferch, Nina Jährling, Katja Heinrich, Ulrike Hoeckendorf, Gerhard K. H. Przemeck, Matthias Munding, Olaf Groß, Timm Schroeder, Marion Horsch, E. Loraine Karran, Aneela Majid, Stefan Antonowicz, Johannes Beckers, Martin Hrabé de Angelis, Hans-Ulrich Dodt, Christian Peschel, Irmgard Förster, Martin J. S. Dyer, and Jürgen Ruland. Prdm6 is essential for cardiovascular development in vivo. PLoS ONE, 8(11):e81833, November 2013. URL: http://dx.doi.org/10.1371/journal.pone.0081833, doi:10.1371/journal.pone.0081833. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0081833)